Venetoclax is an oral BH3 mimetic highly selective for BCL-2 without targeting BCL-XL, with dramatic activity in CLL, notably independent of TP53 mutation (23–25). The gene discussed is BCL2L1; the disease is B-cell chronic lymphocytic leukemia.